Publication: 2077

Publication: 2077

EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Br J Cancer vol 111 (6) 1065-1071

Year:: 2014
Type:: Manuscript
Funding:: NCTN
Endpoint:: Secondary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: ppub

Note:: Preliminary reports from this study were presented at the Thirty-Fifth Annual CTRC-AACR San Antonio Breast Cancer Symposium 3–7 December 2012; San Antonio, TX (abstract 850544).

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:: 4

Parents:: 701
Children:: None

Program:: OGC
Primary Committee:: Breast
Sec. Committees:

Pharmas:
Grants:: U10CA180821 , U10 CA180821, R01 CA-139431, CA-129949, R01 CA139431, P30 CA015083, R01 CA129949, U10 CA25224, U10 CA025224, U10 CA180888

Corr. Author:
Authors:: H Cheng K Ballman M Vassilakopoulou A C Dueck M M Reinholz K Tenner J Gralow C Hudis N E Davidson G Fountzilas A E McCullough B Chen A Psyrri D L Rimm E A Perez

Networks:

Study: NCCTG-N9831
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords:: epidermal growth factor receptor, trastuzumab, tumour biomarker, immunofluorescence assay, breast cancer